739,808 Shares in ImmunityBio, Inc. (NASDAQ:IBRX) Acquired by Rafferty Asset Management LLC

Rafferty Asset Management LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRXFree Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 739,808 shares of the company’s stock, valued at approximately $3,714,000. Rafferty Asset Management LLC owned 0.11% of ImmunityBio as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its position in ImmunityBio by 42.0% during the third quarter. Vanguard Group Inc. now owns 14,675,687 shares of the company’s stock valued at $24,802,000 after purchasing an additional 4,342,386 shares in the last quarter. Armistice Capital LLC bought a new stake in shares of ImmunityBio in the 3rd quarter valued at about $5,874,000. Blair William & Co. IL grew its position in shares of ImmunityBio by 200.7% in the 3rd quarter. Blair William & Co. IL now owns 162,462 shares of the company’s stock worth $275,000 after buying an additional 108,431 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of ImmunityBio by 8.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,142,925 shares of the company’s stock worth $5,737,000 after acquiring an additional 92,991 shares in the last quarter. Finally, Rathbones Group PLC purchased a new stake in ImmunityBio during the third quarter valued at approximately $124,000. 8.58% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lifted their price target on shares of ImmunityBio from $5.00 to $6.00 and gave the stock a “neutral” rating in a report on Monday, April 29th.

Get Our Latest Stock Analysis on ImmunityBio

ImmunityBio Stock Up 0.2 %

Shares of NASDAQ:IBRX opened at $6.10 on Friday. The business’s 50-day moving average is $6.63 and its 200 day moving average is $5.17. ImmunityBio, Inc. has a 1 year low of $1.25 and a 1 year high of $10.53.

ImmunityBio (NASDAQ:IBRXGet Free Report) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.04). The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.03 million. On average, equities research analysts predict that ImmunityBio, Inc. will post -0.75 EPS for the current year.

About ImmunityBio

(Free Report)

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.

See Also

Institutional Ownership by Quarter for ImmunityBio (NASDAQ:IBRX)

Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.